


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.23%
-1.87%
+0.90%
+1.26%
CORT
Corcept Therapeutics
$34.82
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Risk Analysis

Trading above its fair value
CORT Price Performance
$45.64 (-23.71%)
$80.28 (-56.63%)
$83.9 (-58.50%)
$56.4 (-38.26%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading above its fair value
CORT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CORT Street Sentiment is bullish and have positive views on the near-term outlook
CORT has Low risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Dec 17, 2025
Initiate
Neutral
UBS
Nov 25, 2025
Reiterate
Buy
H.C. Wainwright
Oct 20, 2025
Reiterate
Buy
HC Wainwright & Co.
Oct 10, 2025
Reiterate
Buy
HC Wainwright & Co.
Sep 26, 2025
Reiterate
Buy
Canaccord Genuity
What is CORT current stock price?
What are CORT stock strengths?
What is CORT Risk Level?
What is CORT market cap and volume?
What is CORT current Stock IQ?
Should I buy CORT stock right now?
Is CORT a Strong Buy right now?
What does a 'Strong Buy' rating mean for CORT?
What does a 'Strong Sell' rating mean for CORT?
What factors influence CORT's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Recently Viewed
Most Trending
CORT
Corcept Therapeutics
Current Price
$34.82

CORT Price Performance
$45.64 (-23.71%)
$80.28 (-56.63%)
$83.9 (-58.50%)
$56.4 (-38.26%)
CORT Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading above its fair value
CORT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CORT Street Sentiment is bullish and have positive views on the near-term outlook
CORT has Low risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
CORT Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Risk Analysis

Trading above its fair value
CORT Latest Analysis
Corcept Therapeutics: The Bad News Is Priced In. The Ovarian Cancer Upside Is Not.
Fri Feb 20, 2026
Options Exercise: Hazel Hunt At Corcept Therapeutics Realizes $5.53M. On February 11 it was revealed in an SEC filing that Hazel Hunt Chief Scientific Officer at Corcept Therapeutics (NASDAQ:CORT) executed a significant exercise of company stock options.What Happened: A Form 4 filing with the United States Securities and Exchange Commission on Wednesday revealed that
Thu Feb 12, 2026
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT) Hagens Berman Encourages Investors to Contact Firm. SAN FRANCISCO Feb. 9 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushings syndrome) – relacorilant – came on January 30 2026 when Reuters reported that...
Mon Feb 9, 2026
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT. LOS ANGELES Feb. 5 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Thu Feb 5, 2026
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT) Hagens Berman Encourages Investors to Contact Firm. SAN FRANCISCO Feb. 2 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushings syndrome) – relacorilant – came on January 30 2026 when Reuters reported that...
Mon Feb 2, 2026
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT. LOS ANGELES Feb. 2 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Mon Feb 2, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CORT Stock trends
CORT Stock performance
CORT Stock analysis
CORT investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.